SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Metrics to compare | ICU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICUPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −9.3x | −0.6x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price / Book | −3.4x | 1.9x | 2.6x | |
Price / LTM Sales | 103.0x | 3.7x | 3.1x | |
Upside (Analyst Target) | 345.9% | 37.7% | 51.3% | |
Fair Value Upside | Unlock | −4.7% | 7.3% | Unlock |